Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan liposomal (Merrimack Pharmaceuticals, fee52b)
- Development stage
- Approved
- Lead developer
- Merrimack Pharmaceuticals
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Irinotecan liposomal (also known as nanoliposomal irinotecan or nal-IRI) is a nanotherapeutic formulation of the topoisomerase I inhibitor irinotecan. The drug is encapsulated in long-circulating liposome-based nanoparticles using a proprietary intraliposomal stabilization technology, which allows for high drug loading and sustained release. This formulation is designed to improve the pharmacokinetics and biodistribution of irinotecan, protecting it from premature metabolism into its active metabolite, SN-38, and enhancing its accumulation within tumor tissues. It was originally developed by Merrimack Pharmaceuticals as MM-398 and is currently marketed by Ipsen. It is FDA-approved for the treatment of metastatic pancreatic adenocarcinoma in combination with fluorouracil and leucovorin following progression on gemcitabine-based therapy.
- Brand names
- Onivyde
- Other names
- nanoliposomal irinotecannal-IRIirinotecan liposome injectionirinotecan liposomal nanoparticles
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on irinotecan liposomal (Merrimack Pharmaceuticals, fee52b).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan liposomal (Merrimack Pharmaceuticals, fee52b).